logo
Will AI Replace Cybersecurity? Not Quite—But It's Rewriting The Rules

Will AI Replace Cybersecurity? Not Quite—But It's Rewriting The Rules

Forbesa day ago

The Real Battle Is Now AI vs. AI
Put yourself in the mind of a master cybercriminal. Fun, right? Stay with me. I promise this role play exercise will pay off.
Just a few years ago, your illicit schemes were small time. You were content to steal unwitting individuals' personal data, including credit card and social security numbers to buy merchandise on the Dark Web.
Your petty exploits paid off—modestly but steadily. But it was a volume game. You had to keep finding more unsuspecting marks to exploit and more creative ways to turn a profit.
Then came AI.
You quickly learned all about ChatGPT and other forms of generative artificial intelligence. As you did, you thought: why not use this tech to level up—crime-wise?
Armed with new tools you evolved from a petty thief. You developed a budding criminal empire capable of exploiting not just singular victims, but enterprise corporations with billion-dollar balance sheets. After all, that's where the real dough is, right?
Welcome to the new age of cyberwarfare—courtesy of AI.
'The stakes have never been higher,' says Ed Vasko, COO of High Wire Networks, a leading global provider of managed cybersecurity services. A seasoned veteran with 33 years' experience, we sat down to discuss the elephant in the room. 'The cyber war has shifted. It no longer wages between hackers and IT departments. It's now AI versus AI.'
Vasko is not alone in this assessment.
Speaking at DefenseScoop's Google Defense Forum Pentagon last year, military insider Jude Sunderbruch of the Defense Department's Cyber Crime Center warned attendees of future 'AI versus AI conflicts' spreading all the way to the international stage. ''I think we're really just at the start,' Sunderbruch said, later adding that the U.S. and its allies will have to get creative and learn how to best use existing AI systems to gain a leg up on competing intelligence giants like China,' according to Defense One.
The implications go beyond boardrooms and command centers. To appreciate what may be coming, Vasko paints a chilling scenario for the not-so-distant future. Time for more role playing. Now imagine you're the head of a major retailer. For the last few years you've relied on AI supply chain forecasting. Similar to how fintech increasingly depends on AI—not humans—to handle the complexities of trading, artificial intelligence is core to your business' operations.
Without it, you're flying blind.
This reality makes things all the more disturbing when the AI supporting your organization begins behaving erratically, wreaking havoc. Orders stop arriving. Inventory goes out of stock. Even your pricing models collapse.
These internal problems don't stay contained for long. They proliferate externally—in dire ways. Once loyal customers defect. Revenues drop up. And your stock price plummets. But that's not all…
According to Vasko, cyber criminals behind this type of villainy may be thought of as AI buccaneers—digital pirates often paid to instigate corporate espionage and theft. 'Unlike the antiquated variety from centuries past, AI buccaneers know the power of perception—that it's possible to tank a rival company's stock price by spreading lies to disrupt public sentiment.'
To this end, the hits keep on coming for your major retailer company. A video surfaces of your CFO making disturbing comments in a shareholder meeting. The remarks are so inflammatory they go viral, driving your already plummeting stock even lower.
But here's the thing. That CFO video is actually a deepfake. It was produced by Google's Veo 3, similar to extant bogus news anchor content already proliferating the Internet.
True or not, the damage is done.
Within hours, your unscrupulous corporate rivals bask in ignoble victory. Short selling your plunging stock, they make out like bandits—along with their AI buccaneer accomplices, benefitting from your demise.
As Vasko explains, 'Cyber criminals can even now use AI co-pilots to coordinate attacks on corporations, industries, even governments. They're faster, smarter, and more dangerous than anything we've seen before.'
More on that below.
AI co-pilots are but one part of a growing criminal toolkit, capable of automating surveillance, coordinating attacks, and orchestrating malfeasance at scale. What's now possible almost defies belief. Example: AI can analyze thousands of profiles across social media, company directories, and public databases to identify weak links for exploitation. 'Once inside, these same AI tools can poison an organization's internal data lakes—sabotaging predictive systems and decision-making engines from the inside out,' explains Vasko.
This means bad actors needn't limit themselves to stealing personal data. They can expand their scope of attack, going so far as to manipulate market outcomes. Per the above cautionary tale, they can influence how a company performs, how it's perceived, and ultimately, what happens to it long-term.
Hundreds of years ago, back when pirates plundered by sea, countries ravaged by buccaneers authorized so-called privateers to fight off the bad guys. Unfortunately, the U.S. government doesn't allow proactive 'hacking back' in the form of AI privateers. Not even in self-defense.
This is why High Wire Networks and other cybersecurity firms avoid going on the offensive. Instead, they turn to AI-augmented defense platforms to preemptively determine and intercept threats, shifting reactive security into a proactive shield. In other words, they're fighting AI with AI.
'Hyperautomation' is the term Vasko uses to describe the fusion of machine learning and automated decision-making throughout a security stack. In the old model, a cyber victim might be notified of a data breach. 'Dear so and so,' an email might read. 'We regret to inform you that your credit card was compromised.'
That's not so helpful, is it?
Hyperautomation, on the other hand, reacts proactively. Here's how it could work with the above individual scenario. Alerted of a breach, AI could stop it, issue a new credit card, and continually monitor a victim's credit card and exposure.
Many cybersecurity firms employ similar tech at the organizational level. As Cyber Magazine reports, Varonis leverages artificial intelligence to act autonomously as a counterweight to AI-enabled mischief. The company's 'AI Shield' offers real-time ongoing protection for large organizations. 'By integrating real-time risk analysis, automated risk remediation, behavior-based threat detection, and 24/7 alert response, Varonis' AI Shield empowers enterprises to safely use AI technologies while safeguarding sensitive data.'
Looking forward, the more things change, the more they stay the same. Once upon a time, swashbuckling pirates patrolled the high seas, pilfering valuables from individuals, companies, and governments alike. Nowadays, that threat has migrated from the physical theatre to cyberspace as criminals wield code to rob and steal at will. To survive, much less thrive, tomorrow's organizations would do well to wrest back the power of AI.
Without it? We're surely sunk.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dodgers install protective netting under spot where concrete chunk fell on fan
Dodgers install protective netting under spot where concrete chunk fell on fan

New York Times

time9 minutes ago

  • New York Times

Dodgers install protective netting under spot where concrete chunk fell on fan

LOS ANGELES — Protective netting had been installed Saturday morning where a fan said he was hit with a falling chunk of concrete during a Friday night game between the Los Angeles Dodgers and the New York Yankees at Dodger Stadium. The netting covered an approximately two-foot section that comprises the top deck at the stadium. The concrete underneath was craggy and displayed cracks. The incident happened in Section 10 reserve, an area approximately between home plate and first base. Advertisement Dodger Stadium is 63 years old. 'We are aware of the report. We cannot say anything more until we have all of the information, which we are currently gathering,' the team said in a statement Friday night. It hadn't immediately responded to a new request for comment Saturday morning. A Yankees fan said he was hit with a piece of falling concrete while sitting in his seat at Dodger Stadium tonight. The concrete hit him in the back and he was still in some pain after getting medical attention. READ: — Brendan Kuty 🧟‍♂️ (@BrendanKutyNJ) May 31, 2025 The fan — Ricardo Aquino from Mexico City — told The Athletic a hunk of concrete hit him in the back while he was sitting in his seat. Aquino said he was in some pain, but that the concrete hadn't caused bleeding. Several fans in the area said they also saw the concrete fall and hit him. After the incident, he was visited by security and a police officer, who took the concrete piece with him. Then medical personnel visited with Aquino, who later returned to his seat with an ice pack and stayed for the rest of the game. No other fans reported injuries. Lewis Loy of Wilmington, Calif., told The Athletic he watched the concrete fall and hit Aquino. 'Me personally, to see some rocks fall like that,' Loy said, 'I would be clearing out this whole area. How do you know it's not going to fall anymore? … It could have hit a kid.' In April 1998, a concrete beam fell in Yankee Stadium, forcing the team to cancel two games and play another at Shea Stadium. No fans were in the stands at the time, and nobody was injured. ( Top photo: Brendan Kuty / The Athletic)

Ph+ALL: Post-Induction, Ponatinib Yields Molecular Response
Ph+ALL: Post-Induction, Ponatinib Yields Molecular Response

Medscape

time18 minutes ago

  • Medscape

Ph+ALL: Post-Induction, Ponatinib Yields Molecular Response

In the treatment of newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), patients who fail to achieve initial molecular response with the third-generation tyrosine kinase inhibitor (TKI) ponatinib following induction can nevertheless go on to achieve minimal residual disease (MRD) negativity — and at higher rates than the earlier generation TKI imatinib. 'These results support the clinical benefit and tolerability of continuing ponatinib beyond cycle 3 in patients with newly diagnosed, Ph-positive ALL who do not achieve MRD-negativity by the end of induction,' first author Ibrahim Aldoss, MD, of City of Hope hospital in Duarte, California, told Medscape Medical News . The study was presented this week at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Ph+ ALL, the most common subtype of adult ALL and once associated with a particularly poor prognosis, has seen significantly improved outcomes with TKIs in combination with chemotherapy or steroids. However, even with the third generation of TKIs representing the standard of care, relapses can occur due to variant-acquired resistance, particularly T315I. Ponatinib was designed to address that challenge, effectively inhibiting BCR-ABL1 with or without any single-mutation variants, including T315I. The previous global, phase 3, open-label PhALLCON trial represented the first head-to-head comparison of ponatinib (30 mg/day) with the first-generation imatinib (600 mg/day), along with reduced-intensity chemotherapy followed by monotherapy of either drug until disease progression or unacceptable toxicity. The trial met its primary endpoint of no sign of molecular disease (MRD-negative complete response), which correlates with long-term outcomes, by the end of cycle 3 of induction, with ponatinib showing a significantly higher rate vs imatinib (34.4% vs 16.7%; P = .002), and comparable safety outcomes. Current Post-Hoc Analysis To investigate the key question of the effects of further treatment among the majority of patients who did not achieve MRD negativity by the end of induction, or 3 cycles of low-density chemotherapy, Aldoss and colleagues conducted the current post-hoc analysis of 113 patients (73 receiving ponatinib, 40 imatinib) who continued treatment following the end of induction, Of those patients, 48% in the ponatinib group (n = 35) and 33% with imatinib (n = 13) did achieve MRD negativity after induction cycle 4, day 1. The median duration of MRD negativity was not reached with ponatinib compared with 3.8 months with imatinib treatment. Overall, 16 patients (10 receiving ponatinib, 6 imatinib) went on to have a hematopoietic stem cell transplant (HSCT). Among 140 patients who did not achieve MRD negativity by the end of induction, the median event-free survival was not reached with ponatinib therapy compared with 24.8 months with imatinib. The 2-year rates of event-free survival in the two groups were 82% and 62%, respectively. The rates of treatment-emergent adverse events (TEAEs) were similar in the patients who had not achieved MRD negativity by the end of induction, at 100% with ponatinib and 98% imatinib. In addition, 71% and 54% of patients, respectively, had a dose modification (discontinuation, reduction, or interruption) due to TEAEs. Of the 48 patients with MRD negativity after cycle 4, day 1, 100% of patients in each treatment group had TEAEs, and 69% and 62% had dose modification due to TEAEs. Vascular Toxicities Avoided With Lower Dose While ponatinib has previously been associated with increased vascular toxicity and arterial occlusive events, particularly among patients receiving higher doses for longer periods, those events were rare in the current study and not significantly different between the two arms, Aldoss said. He added that the improvement is likely the result of a lowering of the initial dose in the PhALLCON study to 30 mg/day compared with the prior use of 45 mg/day — and a further reduction to 15 mg/day after induction likely helped reduce those effects. 'We feel that using a more optimized, safer lower dose was actually the reason why we're seeing comparable safety and lower arterial occlusive events in this study,' Aldoss said. The benefits were observed across the evaluated subgroups, including patients older than age 60 years, which is important due to previous research showing some increased risk with ponatinib among older adults. Benefits Extend to Older Patients With more stringent criteria in the trial excluding patients with significant cardiovascular disease, Aldoss noted that, 'if anything, the benefit was actually more prominent in patients older than 60.' He therefore recommended consideration of that criteria in making patient selection. Importantly, in the PhALLCON trial, the proportion of patients in the ponatinib arm who went on to receive HSCT was lower compared with imatinib, which could notably benefit older patients who may not respond as well to such treatment. 'The potency of ponatinib in combination with low-dose chemotherapy or no chemotherapy may render HSCT unnecessary for older or frail patients who achieve a 3-month MRD-negative complete remission,' the authors conclude in the study. While the survival estimation can otherwise require long follow-up analysis, MRD negativity is increasingly seen as an important surrogate measure of long-term survival. In one recent meta-analysis, MRD negativity at the end of induction had a significantly greater prognostic value in terms of event-free survival and long-term survival in patients with PH-positive ALL. The current findings suggest such benefits may be achieved even when there is a delay in MRD negativity status after induction, Aldoss noted. 'This analysis supports [the conclusion] that a clinical benefit in event-free survival is observed, even if you don't achieve the MRD negativity at the end of induction,' he said. Following the publication of the PhALLCON trial, the US Food and Drug Administration granted ponatinib accelerated approval for the indication of Ph-positive ALL in March 2024. In an accompanying editorial, Jacqueline S. Garcia, MD, of the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, and colleagues speculated about the role of ponatinib in the context of other promising options. 'It is unclear whether PhALLCON's ponatinib regimen will be preferred against second-generation tyrosine kinase inhibitors, especially regimens that incorporate blinatumomab or allosteric BCR-ABL1 inhibitors,' they write. Importantly, with long-term data showing durable hematologic and molecular responses with combined dasatinib and blinatumomab, thereby offering a chemotherapy-free and toxicity-sparing induction and consolidation regimen, for instance, the option of ponatinib and reduced-intensity chemotherapy 'may not be the optimal first choice for all Ph+ ALL patients,' they say. A notable limitation of the study was that MRD was not assessed with next-generation sequencing (NGS), Pamela Sung, MD, PhD, an assistant professor in the Departments of Medicine and Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, who co-moderated the ASCO session, told Medscape Medical News . 'NGS is more sensitive and specific than BCR-ABL1 PCR for B-ALL MRD detection,' she said. 'It is increasingly being recognized that multi-lineage or 'CML-like' ALL exists, where patients are MRD-positive by BCR-ABL PCR but negative by NGS.' Such patients have a similar relapse rate to those who are MRD-negative by both measures, but it is not known how many patients experience such discordance, Sung noted. The findings are nevertheless important, not so much in showing the rate of MRD at a certain point in time, but the potential trajectory in MRD over the course of treatment, Sung noted. 'Typically, we would continue the current therapy regimen so long as the MRD is continuing to decrease,' she explained. 'However, if unable to clear at the end of 1 to 2 cycles of consolidation, we would recommend allogeneic transplant if eligible. 'These new data support this strategy, using a high potency TKI with few deaths and relapses in the ponatinib arm (10%) for this subset of patients that were MRD-positive at the end of induction. 'Nearly half of patients converted to MRD-negative by the end of treatment with ponatinib, many of whom were negative at [a deeper molecular response] of MR4.5.' The study was sponsored by Takeda Development Center Americas, Inc.

'MobLand' Release Schedule: When the Finale Drops on Paramount Plus
'MobLand' Release Schedule: When the Finale Drops on Paramount Plus

CNET

time20 minutes ago

  • CNET

'MobLand' Release Schedule: When the Finale Drops on Paramount Plus

If you're a Paramount Plus drama with "Land" in its title, viewers will seemingly show up for you. The streamer's new crime series MobLand — and the Taylor Sheridan shows Landman and 1923 — make up the top three launches in Paramount Plus history. It could be Tom Hardy or Guy Ritchie bringing in eyeballs, but I'm sticking with my "Land" theory. MobLand premiered in late March and stars Hardy as a fixer for a crime family who clashes with another family "in a war that threatens to topple empires and lives," according to the streaming service. Pierce Brosnan and Helen Mirren are part of the star-studded cast, and Ritchie directed the first two episodes and serves as an executive producer. MobLand shares a creator, Ronan Bennett, with Peacock's The Day of the Jackal. As of this writing, the show has a 74% score on Rotten Tomatoes. If you're caught up on the series so far, here's how to watch the finale. When to watch MobLand on Paramount Plus In the US, the first nine episodes of MobLand are now streaming on Paramount Plus. The tenth will debut on Sunday. Here's a release schedule for the rest of the season: Episode 10: The Beast in Me — June 1 Paramount Plus subscriptions cost $8 or $13 per month, depending on the tier you select. Both give you access to MobLand. The entry-level Essential plan is ad-supported. The pricier Showtime plan removes most ads and includes downloads and Showtime programming. You can also purchase a full year of either plan and save some money versus paying each month individually.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store